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 IgA in humans is represented by two sub-
classes, IgA1 and IgA2. In the circulation, 
about 85 % of IgA is of the IgA1 subclass. 1 
IgA1, present only in humans and homi-
noid primates, is glycosylated and contains 
 N -linked and  O -linked glycans ( Figure 1 ). 
IgA2, in contrast, contains only  N -linked 
glycans because of a hinge-region segment 
in IgA2 that is much shorter than that in 
IgA1. IgA is produced by terminally dif-
ferentiated plasma cells and, when it is 
associated with a J chain, it forms dimers 
and larger polymers. In humans, IgA-pro-
ducing cells in the bone marrow, lymph 
nodes, and spleen are the most important 
sources of the circulatory IgA. Th e secre-
tory forms of IgA (both subclasses) origi-
nate from a receptor-mediated transcytosis 
of polymeric (that is, J chain-containing) 
IgA across epithelial cells; such secreted 
IgA molecules acquire a part of the recep-
tor (polymeric immunoglobulin receptor) 
that remains associated with IgA, which is 
called the secretory component. 
 Circulatory IgA displays a short half-life, 
about 5 days, although only trace amounts 
of monomeric IgA1 from the circulation 
enter external secretions. This rapid 
removal from the circulation is explained 
by the catabolic degradation in the liver, the 
major site for the catabolism of IgA of 
both subclasses, as well as of other glyco-
proteins. 2 Glycans, through their specifi c 
composition and surface availability, 
are important factors that infl uence the 
catabolic degradation of IgA and other 
glycoproteins, aft er their binding to the 
asialoglycoprotein receptor on the cell 
surfaces of hepatocytes. Th is receptor binds 
IgA molecules via their terminal galactose 
and  N -acetylgalactosamine, 3 whereby the 
immunoglobulin is internalized and cata-
bolically degraded. 4 
 It was noted long ago that in many situ-
ations in which the liver has been exten-
sively damaged, for example, by ethanol 
abuse or viral infections, the normal 
hepatic metabolic function has been com-
promised, leading to clinically manifested 
secondary immune complex renal dis-
eases. 5 Th ese secondary renal diseases are 
frequently associated with mesangial IgA 
deposits. 6 Until now, it has been speculated 
that the development of IgA deposits was 
due mostly to the loss of catabolic function 
of the liver and the consequential accumu-
lation of IgA in the circulation. However, 
Tissandi é and colleagues 7 (this issue) now 
describe glycosylation abnormalities of 
IgA1 in the circulation of patients with 
alcoholic cirrhosis and secondary IgA 
nephropathy. Their important study 
delineates some specific patho genetic 
changes that distinguish this particular 
type of secondary IgA nephropathy from 
primary IgA nephropathy. 
 In primary IgA nephropathy, mesangial 
immunodeposits contain IgA1 with galac-
tose-defi cient  O -linked glycans, probably 
derived from circulating immune com-
plexes consisting of galactose-deficient 
IgA1 and IgG or IgA1 antibodies specifi c 
to the aberrantly glycosylated IgA1. 8 Th ese 
immune complexes are ineffi  ciently cat-
abolized and preferentially deposit in the 
mesangium and activate the resident 
mesangial cells that, in turn, proliferate and 
produce extracellular matrix. 9 Tissandi é 
and colleagues 7 identifi ed some similar 
features as well as distinctive characteristics 
of IgA1 and IgA-containing immune com-
plexes in the circulation of patients with 
primary IgA nephropathy and alcoholic 
cirrhosis. Similar features included aber-
rant  O -glycosylation, immune complex 
formation, and CD71 upregulation in renal 
biopsy specimens. Unique to the patients 
with alcoholic cirrhosis were distinct  N -
glycosylation profi les of IgA1, an increase 
of monogalactosylated biantennary gly-
cans, and a decrease of galactosylated and 
sialylated biantennary glycans ( Figure 1 ). 
Some fi ndings depended on the severity of 
the cirrhosis, defined clinically by the 
Child – Pugh score. In patients with 
advanced disease (class C) compared with 
those with compensated disease (class A), 
the serum levels of IgA and secretory IgA 
were higher, the defects in galactosylation 
or sialylation of IgA1 were more pro-
nounced, and circulating IgA – IgG com-
plexes were detected. Patients with 
advanced alcoholic cirrhosis had more 
severe renal impairment, as manifested by 
proteinuria and decreased renal clearance. 
However, the precise mechanisms for the 
renal injury are not yet clear, because the 
circulating IgA – IgG immune complexes 
failed to increase proliferation of cultured 
human mesangial cells as occurs in patients 
with primary IgA nephropathy. Th is labo-
ratory observation has been considered the 
explanation for the hallmark histological 
features of primary IgA nephropathy, 
increased mesangial cells and mesangial 
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 Tissandi é and colleagues report in this issue on their studies of IgA1 
glycosylation and biological activities of IgA1-containing circulating 
immune complexes in patients with alcoholic cirrhosis who developed 
secondary renal disease with IgA deposits, secondary IgA nephropathy. 
Their seminal findings demonstrate abnormal glycosylation of IgA1 
 N -linked as well as  O -linked glycans. Furthermore, their work reveals 
unique biological properties of immune complexes in these patients 
as compared with those in patients with primary IgA nephropathy. 
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matrix. Th us, while aberrant glycosylation 
of IgA1 and the presence of IgA-containing 
immune complexes may be central to IgA 
nephropathy of its primary form and are 
found in the early stages of alcoholic cir-
rhosis, the pathways in the pathogenesis of 
the renal injury apparently diff er. It would 
be useful to know whether the aberrant 
glycosylation of the circulatory IgA1 in the 
patients with cirrhosis originates from the 
abnormal biosynthesis in IgA1-producing 
cells, as with primary IgA nephropathy, 8 or 
whether it is based on preferential removal 
of galactosylated forms of IgA1 by the 
residual catabolic function of the liver. 
 Th e study by Tissandi é and colleagues 7 
opens many opportunities to ask new spe-
cifi c questions about the pathogenesis of 
IgA-associated renal diseases. For exam-
ple, regarding the  N -linked glycans: What 
are the mechanisms of the abnormal gly-
cosylation of  N -linked glycans? Does it 
aff ect predominantly CH2 or tail  N -linked 
glycans, or both? Does this abnormality 
involve dysregulation of   1,4-galactosyl-
transferase as is the case in chronic infl am-
matory diseases that result in the 
production of galactose-defi cient IgG? 10 
Is this abnormal regulation of the enzy-
matic activity related to alcohol directly or 
indirectly, for example, via cytokines? 
Regarding the  O -linked glycans: Is the 
aberrant  O -glycosylation of IgA1 in pri-
mary and secondary IgA nephropathy 
identical as to the specifi c sites of attach-
ment of the aff ected glycans, and is the 
aberrancy infl uenced by similar or diff er-
ent genetic markers? What is the compo-
sition of immune complexes in the 
circulation of patients with alcoholic cir-
rhosis? What makes the immune com-
plexes in primary and secondary forms of 
IgA nephropathy lead to a differential 
response by mesangial cells? Th ese and 
other issues are now fully appropriate for 
further study, as they are apparently 
directly related to the pathogenesis of sec-
ondary IgA nephropathy and may also 
provide additional clues about the patho-
genesis of primary IgA nephropathy. 
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 Figure 1  |  Schema of monomeric IgA1 and structures of  O -linked and  N -linked glycans. 
( a ) Monomeric IgA1 contains two heavy chains and two light chains. Each heavy chain has two sites 
with attached  N -linked glycans and up to six  O -linked glycans.  O -linked glycans are in the hinge 
region between CH1 and CH2, a segment that is much longer in IgA1 than in IgA2. The  N -glycans 
are in the Fc portion of the molecule in CH2 and CH3 ( ‘ tail ’ glycans). Two or more monomers can 
be linked via J chain to form dimeric or polymeric IgA1. ( b ) Structures of  O -linked glycans on 
circulatory IgA1 can consist of galactose-deficient IgA1 (structures I and II) and galactosylated core 
1 glycans (structures II – VI). Biosynthesis starts with structure I and goes through to structure III, 
which may be sialylated (structures IV – VI). Structure II represents a terminal modification. Empty 
squares,  N -acetylgalactosamine; empty circles, galactose; filled diamonds, sialic acid. ( c ) Structures 
of  N -linked biantennary glycans on circulatory IgA1. G0 means  N -glycan without any galactose; 
G2 means  N -glycan with two galactose molecules; G2S2 means  N -glycan with two galactose 
molecules and two sialic acid residues. Terminal decoration proceeds from G0 to G2 and G2S2 
structures. Empty triangles, fucose; green circles, mannose; blue squares,  N -acetylglucosamine. 
Fucose may or may not be present. Tail glycans usually have fucose attached, whereas the CH2 
glycans usually have no fucose. 
commentar y
1254   Kidney International (2011) 80 
Lamm ME  et al. (eds) .  Mucosal Immunology .  3rd 
edn, vol 1 .  Elsevier Academic Press: Amsterdam , 
 2005 ,  pp  153 – 181 . 
 2 .  Moldoveanu  Z ,  Moro  I ,  Radl  J  et al.  Site of catabolism 
of autologous and heterologous IgA in non-human 
primates .  Scand J Immunol  1990 ;  32 :  577 – 583 . 
 3 .  Stockert  RJ ,  Kressner  MS ,  Collins  JD  et al.  IgA 
interactions with the asialoglycoprotein receptor . 
 Proc Natl Acad Sci USA  1982 ;  79 :  6229 – 6231 . 
 4 .  Tomana  M ,  Kulhavy  R ,  Mestecky  J .  Receptor-
mediated binding and uptake of immunoglobulin A 
by human liver .  Gastroenterology  1988 ;  94 :  887 – 892 . 
 5 .  McGuire  BM ,  Julian  BA ,  Bynon  Jr  JS  et al. 
 Glomerulonephritis in patients with hepatitis C 
cirrhosis undergoing liver transplantation . 
 Ann Intern Med  2006 ;  144 :  735 – 741 . 
 6 .  Pouria  S ,  Barratt  J .  Secondary IgA nephropathy . 
 Semin Nephrol  2008 ;  28 :  27 – 37 . 
 7 .  Tissandi é  E ,  Morelle  W ,  Berthelot  L  et al.  Both 
IgA nephropathy and alcoholic cirrhosis feature 
abnormally glycosylated IgA1 and soluble 
CD89 – IgA and IgG – IgA complexes: common 
mechanisms for distinct diseases .  Kidney Int 
 2011 ; 80:  1352 – 1363 . 
 8 .  Suzuki  H ,  Fun  R ,  Zhang  Z  et al.  Aberrantly 
glycosylated IgA1 in IgA nephropathy patients 
is recognized by IgG antibodies with restricted 
heterogeneity .  J Clin Invest  2009 ;  119 :  1668 – 1677 . 
 9 .  Novak  J ,  Mestecky  J .  IgA immune-complex .  In: 
Lai KN (ed) .   Recent Advances in IgA Nephropathy . 
 Imperial College Press and World Scientific: 
Hong Kong ,  2009 ,  pp  177 – 191 . 
 10 .  Arnold  JN ,  Wormald  MR ,  Sim  RB  et al.  The impact 
of glycosylation on the biological function and 
structure of human immunoglobulins .  Annu Rev 
Immunol  2007 ;  25 :  21 – 50 . 
 Predicting an allograft ’ s fate 
 Thomas  Fehr 1 and  Clemens D.  Cohen 1 , 2  
 Renal allografts inevitably develop progressive morphological and 
functional deterioration. Naesens  et al. now report on a transcriptomic 
approach to identify transcriptional markers that might predict rapid 
development of chronic damage even in histologically unremarkable 
allografts. The data indicate that processes similar to those seen in overt 
acute rejection are also involved in chronic allograft nephropathy. 
Identifying such  ‘ sub-morphological ’ markers should help us to better 
understand biological processes leading to chronic allograft failure. 
 Kidney International (2011)  80, 1254 – 1255;  doi: 10.1038/ki.2011.328 
 Destiny — our cultural heritage is rich in 
stories telling about humans who struggle 
with the foreseen and attempt to change 
their fate. Greek legends, Shakespeare ’ s 
drama, and even modern science fi ction 
movies deal with the dilemma of being 
unable to outmaneuver the prediction. Cur-
rently, we are experiencing an era of  ‘ predic-
tive medicine. ’ Modern techniques have 
been successful in predicting the outcome 
of disease for specifi c cohorts. In parallel, 
they help to focus on candidate molecules 
and biological processes centrally involved 
in disease processes. Hence molecular 
markers might lead to novel therapeutic 
concepts. However, until a potential inter-
vention is achieved, any molecular predic-
tion appears as inexorable as destiny. 
 One example of a currently inevitable 
destiny in medicine is chronic allograft  
failure. Most renal allograft s have an ines-
capable fate of interstitial fibrosis and 
tubular atrophy accompanied by progres-
sive loss of allograft  function. 1 Th e intro-
duction of potent immunosuppressant 
therapy did not change this course funda-
mentally. Th e burden of failing allograft s 
is growing. It leads to medical compli-
cations in the individual patient and 
challenges to the transplant physician fac-
ing a growing number of sensitized patients 
awaiting retransplantation, increasing 
organ shortage, and rising costs. 
 Allograft fibrosis may have multiple 
origins, including acute and chronic 
rejection, infection, drug toxicity, and 
progression of donor-derived diseases 
such as hypertensive damage. Many of 
these factors are directly or indirectly 
linked to alloimmunity, as evidenced by 
the fact that these processes do not occur 
in isograft s or tolerant patients. Th us it 
would be of utmost interest to identify the 
causative, damaging process as early as 
possible. In the case of a clinically acute 
rejection we are able to identify and treat 
it successfully, although oft en not without 
scarring and a permanent loss of function. 
By contrast, we can barely infl uence the 
course of histopathologically identifi able 
chronic transplant alterations, such as 
transplant glomerulopathy, glomerulo-
sclerosis, interstitial fi brosis, and tubular 
atrophy. Recent prospective studies on 
immunosuppressive treatment of sub-
clinical morphological alterations failed 
to show a benefi t. 2,3 A next logical step 
could be to look even earlier for markers 
indicating the future development of 
chronic damage in histologically normal 
allograft s. Transcriptomic analysis might 
be a promising tool to develop molecular 
classifi ers to predict future allograft  dys-
function 4 by detecting even  ‘ sub-morpho-
logical ’ alterations ( ‘ transcriptomic 
window, ’  Figure 1 ). 
 Now the group of Minnie Sarwal  (Naesens 
 et al. , 5 this issue) has taken this step by 
generating a comprehensive set of 
genome-wide expression data from allo-
graft  biopsies of a pediatric transplant 
cohort. Biopsies with chronic allograft  
damage but without obvious infl amma-
tory alteration showed altered expression 
levels of genes known to be linked to 
immunological processes. Th e authors 
confi rmed this transcriptomic fi ngerprint 
in an independent set of protocol biopsies 
taken two years after transplantation. 
Interestingly, they could also demonstrate 
that a smaller set of transcripts, again 
mainly indicating activation of immune 
responses, were more prominently altered 
in biopsies of patients who progressed to 
histological chronic allograft  damage 18 
months later compared with individuals 
with no such progression. Th ese data from 
protocol biopsies taken 6 months aft er 
transplantation suggest a continuous 
induction of immunological processes in 
allografts prone to develop chronic 
 damage more rapidly. In transplant 
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